1-3 of 3
Daniel Filippa, MD
Close
Sort by
Journal Articles

Enhanced In Vivo activation of Adoptively Transferred Genetically Targeted T Cells Following Cyclophosphamide Chemotherapy: Initial Results From a Phase I Clinical Trial Treating CLL Patients with Autologous CD19-Targeted T Cells.

Renier J. Brentjens, MD, PhD, Daniel Hollyman, PhD, Jae Park, MD, Elmer Santos, MD, PhD, Raymond Yeh, Ph.D., Jolanta Stefanski, Clare Taylor, PhD, Mark A. Weiss, MD, Daniel Filippa, MD, Isabelle Riviere, PhD, Michel W Sadelain, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 3436.
https://doi.org/10.1182/blood.V114.22.3436.3436
Published: 2009
Journal Articles

Relapsed and Primary Refractory Diffuse Large B-Cell Lymphoma: Improving Outcome by Incorporating Involved Field Radiotherapy into a Comprehensive Second-Line High-Dose Therapy Strategy.

Bradford S. Hoppe, MD, Joachim Yahalom, MD, Tarun Kewalramani, MD, Paul A. Hamlin, MD, David Rice, RN, Daniel Filippa, MD, Jocelyn Maragulia, Alandra Weaver, Craig H. Moskowitz, MD
Journal: Blood
Blood (2007) 110 (11): 1893.
https://doi.org/10.1182/blood.V110.11.1893.1893
Published: 2007
Journal Articles

Expert Second Opinion Pathology Review of Lymphoma in the Era of the World Health Organization Classification.

Matthew J. Matasar, MD, MS, Weiji Shi, MS, Jonathan Silberstien, MD, Julie T. Feldstein, MD, Daniel Filippa, MD, Andrew D. Zelenetz, MD, PhD, Ariela Noy, MD
Journal: Blood
Blood (2007) 110 (11): 3317.
https://doi.org/10.1182/blood.V110.11.3317.3317
Published: 2007